The FDA’s reversal of its earlier refusal to review mRNA-1010, the seasonal flu vaccine being developed by Moderna, accelerated a revival of Moderna shares that has been in progress over recent months ...

FDA issues a Refusal to File letter to Moderna (NasdaqGS:MRNA) for its influenza vaccine candidate mRNA-1010. The decision centers on the choice of clinical trial comparator, not on safety or efficacy ...

Booster vaccines reduced the risk of COVID‑19–related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research led by the ...

A look at how executive power has expanded from Lincoln to COVID-19—and why it’s driving a new rise in libertarianism.

Moderna Inc.’s settlement to end a lawsuit over technology used in its Covid-19 vaccine caps its potential exposure at $2.25 ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

Moderna agreed to pay up to $2.25 billion to settle a long‑running COVID vaccine patent dispute. The deal ends years of legal challenges.

Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the ...

The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

The recommendation from regulators paves the way for the shot’s approval in the European Union at a time the company is ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending ...